EP 4192833 A1 20230614 - PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES
Title (en)
PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES
Title (de)
PHARMAZEUTISCH AKTIVE HETEROZYKLISCH-SUBSTITUIERTE PYRAZOLO[1,5-A PYRIMIDIN-DERIVATE
Title (fr)
DÉRIVÉS DE PYRAZOLO[1,5-A]PYRIMIDINE À SUBSTITUTION HÉTÉROCYCLIQUE PHARMACOLOGIQUEMENT ACTIFS
Publication
Application
Priority
- HU P2000254 A 20200805
- IB 2021057180 W 20210805
Abstract (en)
[origin: US2023286988A1] The invention relates to new pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention also relates to the process for producing such compounds and key intermediates used in the process. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention also provides a method for manufacture of medicaments useful in the treatment of such disorders.
IPC 8 full level
C07D 487/04 (2006.01); A61K 31/519 (2006.01); A61P 19/00 (2006.01); A61P 25/00 (2006.01)
CPC (source: EP IL KR US)
A61K 31/519 (2013.01 - EP IL KR); A61P 25/00 (2018.01 - EP IL KR US); C07D 487/04 (2013.01 - EP IL KR US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
US 2023286988 A1 20230914; AR 123154 A1 20221102; AU 2021319420 A1 20230316; AU 2021319420 A8 20230330; BR 112023001060 A2 20230307; CA 3185566 A1 20220210; CL 2023000352 A1 20230901; CN 116075514 A 20230505; CO 2023001367 A2 20230216; EP 4192833 A1 20230614; IL 300208 A 20230301; JP 2023536197 A 20230823; KR 20230049677 A 20230413; MX 2023001444 A 20230308; PE 20240107 A1 20240122; TW 202220992 A 20220601; WO 2022029666 A1 20220210
DOCDB simple family (application)
US 202118040456 A 20210805; AR P210102183 A 20210805; AU 2021319420 A 20210805; BR 112023001060 A 20210805; CA 3185566 A 20210805; CL 2023000352 A 20230203; CN 202180058179 A 20210805; CO 2023001367 A 20230208; EP 21755582 A 20210805; IB 2021057180 W 20210805; IL 30020823 A 20230126; JP 2023507435 A 20210805; KR 20237007966 A 20210805; MX 2023001444 A 20210805; PE 2023000205 A 20210805; TW 110128314 A 20210802